Patents Examined by Gary B. Nickol
  • Patent number: 11359022
    Abstract: Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: June 14, 2022
    Assignee: Alpine Immune Sciences, Inc.
    Inventors: Ryan Swanson, Michael Kornacker
  • Patent number: 11359026
    Abstract: The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: June 14, 2022
    Assignees: CHUGAI SEIYAKU KABUSHIKI KAISHA, HOFFMANN-LA ROCHE INC.
    Inventors: Toshiyuki Morichika, Daisuke Kameoka, Yoshimi Imaeda, Terutoshi Maeda, Oliver Boris Stauch
  • Patent number: 11352423
    Abstract: The present disclosure describes a pharmaceutical formulation of an anti-CD19 antibody.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: June 7, 2022
    Assignee: MORPHOSYS AG
    Inventors: Patrick Garidel, Andreas Langer, Martin Hessling, Daniel Weinfurtner, Bodo Brocks
  • Patent number: 11351252
    Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: June 7, 2022
    Assignee: SNIPR Technologies Limited
    Inventor: Jasper Clube
  • Patent number: 11345744
    Abstract: We provide new monoclonal antibody inhibitors of coagulases staphylocoagulase and vWbp for treatment of S. aureus. The monoclonal antibodies are useful in targeting the SC N-terminus of SC and vWbp (respectively) and inhibiting prothrombin activation. The monoclonal antibodies are able to bind to and interfere with, modulate, and/or inhibit the binding interactions between the coagulase protein and its ligand protein prothrombin in blood and tissues. The antibodies are effective in inhibiting the activation of prothrombin.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: May 31, 2022
    Inventor: William R Church
  • Patent number: 11338000
    Abstract: Provided is a use of Butyribacter intestini in preventing and/or treating inflammation-related diseases. Specifically, in the present disclosure, it was firstly discovered that Butyribacter intestini has the function of preventing and/or treating inflammation-related diseases (for example, inflammatory bowel disease, such as ulcerative colitis, gastritis, and common enteritis; and rheumatoid arthritis).
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: May 24, 2022
    Assignee: BGI SHENZHEN
    Inventors: Yuanqiang Zou, Liang Xiao, Xiaoping Li, Jinghong Yu, Chuan Liu
  • Patent number: 11332751
    Abstract: The present disclosure includes methods and components for production of valuable industrial compounds in yeast. In an embodiment, the present invention provides a nucleic acid construct with increased stability for gene expression or gene editing comprising: a nucleic acid sequence encoding one or more of SEQ ID NO: 1-8 (CENs 1-8); and one or more regulatory elements functional in a yeast cell. In an embodiment of the present invention the nucleic acid constructs are vectors, preferably episomal vectors. High expression promoters, as well as methods for increasing production of compounds such as aromatics are disclosed.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: May 17, 2022
    Assignee: Iowa State University Research Foundation, Inc.
    Inventors: Zengyi Shao, Mingfeng Cao, Miguel Suastegui, Meirong Gao
  • Patent number: 11324739
    Abstract: Novel combination therapies involving nitroxoline, its analogue or pharmaceutically acceptable salt thereof with at least one additional anti-cancer chemotherapy or immunotherapy agent are described. Related kits, pharmaceutical compositions and methods of production arlinee also described.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: May 10, 2022
    Assignee: Jiangsu Yahong Meditech Co., Ltd.
    Inventors: Ke Pan, Peng Huang, Qiang Li
  • Patent number: 11324814
    Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: May 10, 2022
    Assignee: Protein Potential, LLC
    Inventors: Yun Wu, Dennis J. Kopecko, B. Kim Lee Sim, Stephen L. Hoffman
  • Patent number: 11325979
    Abstract: The present invention provides, among other things, a method of treating a subject with infection-induced hyperinflammation comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of hyperinflammation. The present invention also provides, among other things, a method of inhibiting or reducing cytokine release syndrome (CRS) or acute respiratory distress syndrome (ARDS) in a subject comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of CRS or ARDS.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: May 10, 2022
    Inventors: Joe Pirrello, John Paolini, Eben Tessari
  • Patent number: 11319381
    Abstract: The present invention relates to active form specific anti-Rho GTPase conformational single domain antibodies and their uses in particular in the therapeutic and diagnostic fields. In particular, the present invention relates to a single domain antibody wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90% of identity with the amino acid sequences of the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) single domain antibody which are defined in Table B.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: May 3, 2022
    Assignees: INSERM (Institut National de la Santéet de la Recherche Médicale), UniversitéPaul Sabatier Toulouse III, Institut Claudius Regaud
    Inventors: Aurelien Olichon, Laura Keller, Gilles Favre, Nicolas Bery, Patrick Chinestra
  • Patent number: 11319356
    Abstract: The present invention provides a fusion polypeptide comprising a first domain and a second domain, wherein the first domain comprises a polypeptide ligand which binds to a cell surface-associated antigen and the second domain comprises aglycosylated interferon ? 2b (IFN?2b) having a sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The aglycosylated IFN?2b further comprises one or more amino acid substitutions or deletions which attenuate the activity of the aglycosylated IFN?2b.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: May 3, 2022
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Collette Behrens, Anthony Doyle, Adam Clarke, Matthew Pollard, Teresa Domagala
  • Patent number: 11318207
    Abstract: The present invention relates to a method for PEGylating interferon beta.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: May 3, 2022
    Assignee: BIOGEN MA INC.
    Inventors: Robert S. Gronke, Orlando A. Jaquez
  • Patent number: 11311581
    Abstract: The present invention relates to the combination of spirulina and palmitoylethanolamide (PEA) and/or pharmaceutically acceptable derivates or salts thereof, pharmaceutical formulations comprising the combination of spirulina and PEA and/or pharmaceutically acceptable derivates or salts thereof, optionally together with at least one physiologically acceptable excipient, and the use of the combination of spirulina and PEA and/or pharmaceutically acceptable derivates or salts thereof and formulations which include the said combination, for use in the prevention and/or treatment of tissue hyperactivation states, in the prevention and/or treatment of inflammatory pathologies, in the prevention and/or treatment of alterations in cardiac and/or coronary tissue, in the prevention and/or treatment of alterations in the vascular tissue, in the prevention and/or treatment of ophthalmic pathologies, preferably in the prevention and/or treatment of macular degeneration pathologies and glaucoma, in the prevention and/or tr
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: April 26, 2022
    Assignee: AGAIN LIFE ITALIA SRL
    Inventors: Raffaele Migliaccio, Carmela Migliaccio, Antonella Sardei
  • Patent number: 11305001
    Abstract: The present embodiments provide for an S. aureus (SA) Multiple Antigen Presenting System (MAPS) immunogenic composition comprising an immunogenic polysaccharide which induces an immune response, where at least one S. aureus (SA) peptide or polypeptide antigen is associated to the immunogenic polysaccharide by complementary affinity molecules. In some embodiments, the immunogenic polysaccharide can be an antigenic capsular polysaccharide of a Type 5 or Type 8 from S. aureus, or alternatively, a different immunogenic capsular or noncapsular polysaccharide, and where the protein or peptide SA antigens are indirectly linked via an affinity binding pair. The present SA-MAPS immunogenic compositions can elicit both humoral and cellular immune responses to the immunogenic polysaccharide and one or multiple SA antigens at the same time.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: April 19, 2022
    Assignee: The Children's Medical Center Corporation
    Inventors: Richard Malley, Fan Zhang, Yingjie Lu
  • Patent number: 11298385
    Abstract: The present invention relates to a microorganism for drug delivery, which has been transformed with a gene construct comprising a therapeutically active peptide, which can be delivered safely into the intestines through oral administration, and which can express and secrete the therapeutic peptide in the gastrointestinal tract, and also relates to a pharmaceutical composition for prevention or treatment of gastrointestinal disease, which includes the same. The present invention is directed to a lactic acid bacteria drug delivery system capable of overexpressing and secreting a lactic acid bacteria-derived anticancer protein, which is developed by introducing the anticancer protein into a lactic acid bacteria expression and secretion system. It is expected that the lactic acid bacteria drug delivery system will be widely used as a natural protein therapeutic agent against gastrointestinal disease in the medical field.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: April 12, 2022
    Assignee: Cell Biotech Co., Ltd.
    Inventor: Myung Jun Chung
  • Patent number: 11291720
    Abstract: The present invention belongs to the fields of tumor therapy and molecular immunology, and provides an anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition thereof and use thereof. The monoclonal antibody of the present invention can block the binding of CLTA4 to B7, relieve the immunosuppression on the body by CTLA4, and activate T lymphocytes.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: April 5, 2022
    Assignee: AKESO BIOPHARMA, INC.
    Inventors: Baiyong Li, Yu Xia, Zhongmin Wang, Peng Zhang, Xinghua Pang
  • Patent number: 11291725
    Abstract: The present invention relates to a novel protein formulation. In particular, the invention relates to a liquid pharmaceutical composition of tocilizumab, a method of manufacturing the composition, a kit including the composition, a package including the composition and to methods of treatment using the composition and/or package.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: April 5, 2022
    Assignee: FRESENIUS KABI DEUTSCHLAND GMBH
    Inventors: Jan Jezek, Luca Badiali, David Gerring
  • Patent number: 11291723
    Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: April 5, 2022
    Assignee: SNIPR Technologies Limited
    Inventor: Jasper Clube
  • Patent number: 11291695
    Abstract: The present invention provides a Bacillus subtilis strain selected from the group consisting of a) the strain deposited as DSM32324, b) the strain deposited as DSM32325, and c) a mutant strain of (a) or (b) which has sensitivity for ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline, and chloramphenicol; and has inhibitory activity against E. coli and Clostridium perfringens. The invention further relates to Bacillus compositions comprising at least one Bacillus subtilis strain of the invention, preferably the Bacillus subtilis strain DSM32324 and/or the Bacillus subtilis strain DSM32325, as Direct Fed Microbial (DFM), premix, animal feed additive or animal feed.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: April 5, 2022
    Assignee: CHR. HANSEN A/S
    Inventors: Dorthe Sandvang, Tina Styrishave